Laquinimod for multiple sclerosis

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effectiveness and safety profile of laquinimod as monotherapy or combination therapy versus placebo or approved disease-modifying drugs (DMDs) (IFN-β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide) for modifying disease course in patients with multiple sclerosis (MS).